Karyopharm Therapeutics Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Richard A. Paulson
- Full Time Employees
- 279
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 85 Wells Avenue Newton MA United States of America 02459
- IPO Date
- Nov 6, 2013
- CIK
- 0001503802
- Website
- karyopharm.com
- Similar Companies
- Business
- Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapies targeting nuclear export dysregulation for cancer and other diseases; its lead product, XPOVIO (selinexor), an oral Selective Inhibitor of Nuclear Export (SINE) compound, is approved by the FDA, European Commission, UK Medicines and Healthcare products Regulatory Agency, and Israeli Ministry of Health for multiple myeloma and diffuse large B-cell lymphoma in combination with other agents, and marketed as NEXPOVIO in Europe and the UK; the company advances a pipeline of SINE compounds including eltanexor and four clinical-stage drug candidates for hematologic malignancies and solid tumors such as endometrial cancer and myelofibrosis. Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm maintains operations across the United States, Europe (with presence in Switzerland and Germany), Israel, and China, serving oncology patients through commercial activities, clinical trials, and patient support programs like KaryForward. Recent developments include significant refinancing transactions in May 2024 with HealthCare Royalty and convertible note holders, comprising a $100 million senior secured term loan and amended royalty agreements extending debt maturities to 2028-2029 to fund Phase 3 readouts expected in 2025; a collaboration with Bristol Myers Squibb to evaluate selinexor with mezigdomide in relapsed/refractory multiple myeloma; and Q3 2025 U.S. net product revenue of $32 million for XPOVIO, up 8.5% year-over-year, alongside ongoing inducement grants under its 2022 stock plan.
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis Transcript
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation
Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference
Wall Street Analysts Think Karyopharm Therapeutics (KPTI) Could Surge 70.46%: Read This Before Placing a Bet
Karyopharm Therapeutics Inc. (KPTI) Q1 2026 Earnings Call Transcript
Karyopharm Therapeutics Q1 Earnings Call Highlights
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
Karyopharm to Participate at Upcoming Investor Conferences
Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting
Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Above 50 Day Moving Average – What’s Next?
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of “Moderate Buy” by Brokerages
Short Interest in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Rises By 20.9%
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?